MedTrace Logo

Inhaled Furosemide for Transient Tachypnea of Newborn

NCT04397991 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-08-30

No results posted yet for this study

Summary

This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.

Conditions

  • Respiratory Morbidity

Interventions

OTHER

Furosemide

Patients will receive nebulised furosemide solution 1 mg/kg

OTHER

Placebo

Patients will receive nebulised 0.9% saline

Sponsors & Collaborators

  • Makassed General Hospital

    lead OTHER

Principal Investigators

  • Mariam Rajab, MD · Makassed General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
1 Day
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-02
Primary Completion
2021-08-01
Completion
2021-08-01

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397991 on ClinicalTrials.gov